AARDEX still confirms its leading position in the B2B medication adherence market, closing steadily more new deals with Pharma Companies, Biotech’s, Excellence Centers and Universities, over 30 countries in 2018.

AARDEX still confirms its leading position in the B2B medication adherence market, closing steadily more new deals with Pharma Companies, Biotech’s, Excellence Centers and Universities, over 30 countries in 2018.
Clinical trials rely on accurate data. But what if one of the most important variables whether a patient actually takes the medication is based on guesswork? Traditional methods like pill counts, diaries, or verbal confirmation have long been the standard,
Imagine spending years developing a promising new treatment, only to have its potential clouded by something as simple (and as overlooked) as whether or not people actually took their pills. This isn’t just a small glitch in the process. In